Stockreport

Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]

Spyre Therapeutics, Inc.  (SYRE) 
PDF and a long half-life, with plans to advance into Phase 2 studies and ongoing capital-raising efforts supporting continued development. An interesting insight is the co [Read more]